Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models

Andrea Casazza, Xi Fu, Irja Johansson, Lorena Capparuccia, Fredrik Andersson, Alice Giustacchini, Mario Leonardo Squadrito, Mary Anna Venneri, Massimiliano Mazzone, Erik Larsson, Peter Carmeliet, Michele De Palma, Luigi Naldini, Luca Tamagnone and Charlotte Rolny

Arterioscler Thromb Vasc Biol. 2011;31:741-749; originally published online January 4, 2011;
doi: 10.1161/ATVBAHA.110.211920

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/31/4/741

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2010/12/28/ATVBAHA.110.211920.DC1.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models

Andrea Casazza, Xi Fu, Irja Johansson, Lorena Capparuccia, Fredrik Andersson, Alice Giustacchini, Mario Leonardo Squadrito, Mary Anna Venneri, Massimiliano Mazzone, Erik Larsson, Peter Carmeliet, Michele De Palma, Luigi Naldini, Luca Tamagnone, Charlotte Rolny

Objective—The role of semaphorins in tumor progression is still poorly understood. In this study, we aimed at elucidating the regulatory role of semaphorin 3A (SEMA3A) in primary tumor growth and metastatic dissemination.

Methods and Results—We used 3 different experimental approaches in mouse tumor models: (1) overexpression of SEMA3A in tumor cells, (2) systemic expression of SEMA3A following liver gene transfer in mice, and (3) tumor-targeted release of SEMA3A using gene modified Tie2-expressing monocytes as delivery vehicles. In each of these experimental settings, SEMA3A efficiently inhibited tumor growth by inhibiting vessel function and increasing tumor hypoxia and necrosis, without promoting metastasis. We further show that the expression of the receptor neuropilin-1 in tumor cells is required for SEMA3A-dependent inhibition of tumor cell migration in vitro and metastatic spreading in vivo.

Conclusion—In sum, both systemic and tumor-targeted delivery of SEMA3A inhibits tumor angiogenesis and tumor growth in multiple mouse models; moreover, SEMA3A inhibits the metastatic spreading from primary tumors. These data support the rationale for further investigation of SEMA3A as an anticancer molecule. (Arterioscler Thromb Vasc Biol. 2011;31:741-749.)

Key Words: angiogenesis ■ molecular biology ■ pathology ■ receptors ■ vascular biology ■ metastasis ■ neuropilin ■ semaphorin ■ tumor

Semaphorins are a highly conserved family of molecules originally identified as axon guidance factors.1,2 Notably, over the past few years, distinct semaphorins have been implicated in additional biological processes, including angiogenesis, immune regulation, and cancer.3,4

See accompanying article on page 721

Semaphorin function is mediated by a family of plasma membrane receptors, the plexins.5 However, most secreted semaphorins (including semaphorin 3A [SEMA3A]) cannot bind to plexins directly; rather, they interact with plexin-associated coreceptors, namely neuropilin-1 (NP1) and neuropilin-2 (NP2).5,6 Interestingly, NPs also bind vascular endothelial growth factor family members and associate in complex with vascular endothelial growth factor receptors,6 playing a crucial role in angiogenesis beyond axon guidance.3 In particular, SEMA3A signaling is fully dependent on the receptor NP1, whereas little is known about the requirement of specific plexins in its receptor complex.

So far, SEMA3A has been reported to inhibit the growth of certain experimental tumors7 and to regulate endothelial cell migration and apoptosis in vitro,8,9 as well as arteriogenesis in the muscle,10 skin vessel permeability,11 and tumor angiogenesis in vivo.12 However, the functional significance of SEMA3A signaling as a molecular target to control tumor progression is still poorly understood. Generally, tumor blood vessels display a chaotic architecture that leads to impaired tumor perfusion, elevated tissue hypoxia, and substantial cell death. It has been shown that antiangiogenic treatments targeting vascular endothelial growth factor signaling can disrupt tumor blood vessels and increase tumor necrosis. However, these therapies, although they cause transient tumor shrinkage, also elicit a prometastatic program in the tumor cells that is driven by hypoxia.13,14 Therefore, strate-
gies that concomitantly target endothelial cells and prevent tumor cell spreading are needed. Here, we show that systemic, as well as tumor-targeted, delivery of SEMA3A inhibits tumor growth in multiple mouse models. This is achieved through SEMA3A-mediated inhibition of blood vessel function, whereas metastatic dissemination is hindered via NP1-mediated signaling in tumor cells.

Methods

Tumor Cell Lines

Tumor cell lines were grown in standard medium supplemented with 1-glutamine and 10% fetal bovine serum (Sigma). 4T1 and 66cl4 spontaneous mouse mammary carcinoma cells were originally derived from a single spontaneous tumor arise in a BALB/c/c3H mouse, isolated by 60 μM 6-thioguanine in vitro selection, and kindly provided by Dr F. Miller (Michigan Cancer Foundation, Detroit, MI). MDA-MB-435 cells are undifferentiated tumor cells derived from either human mammary carcinoma or, as recently found, from human melanoma.16

Lentiviral Vectors

The LV constructs expressing green fluorescent protein (GFP) under different promoters: i.e. Tie2, phosphoglycerate kinase (PGK) and cytomegalovirus (CMV) were previously described.17 The Tie2-3A, PGK-3A, and CMV-3A LVs were generated by cloning the mouse Sem3A cDNA in place of GFP into the Tie2-GFP or PGK-GFP LV or human SEMA3A cDNA into the CMV-GFP LV, respectively. Concentrated vesicular stomatitis virus-G protein (VSVG)- pseudotyped LV stocks were produced and titrated as described previously.18 Tumor cells were transduced by incubation with concentrated LVs for 8 to 12 hours in the presence of 8 μg/mL polybrene.

SDS-PAGE and Western Immunoblotting

Cellular proteins were solubilized in 1% Triton X-100−containing extraction buffer plus inhibitors, as previously described.18 Equal amount of proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and probed with antibodies directed against myc-tag (9E10, Santa Cruz Biotechnology), NP1 (R&D Systems), or β-actin (Santa Cruz Biotechnology), followed by detection using the appropriate secondary antibody and ECL system (Amersham).

Gene Knockdown

NP1 expression was stably knocked down in 4T1 cancer cells using a LV containing a gene-targeted short hairpin RNA against NP1 and a puromycin resistance cassette (Sigma Mission, NM_009152).

Cell Growth Assay

Tumor cells were plated in multiple 96-well dishes (Costar) at an initial density of 1×104 cells/well. After 24 hours of serum starvation, the cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 1-glutamine and 1% fetal bovine serum for 1, 2, and 3, days. Cells were fixed with 11% glutaraldehyde and then stained with 0.5% crystal violet in 20% methanol. The dye was eluted with 10% v/v glacial acetic acid, and the absorbance at 595 nm was determined by using a Titertek Multiskan reader.

Cell Migration Assay

Cell motility was assayed using Transwell chamber inserts (Costar, Cambridge, MA) with a porous polycarbonate membrane (8 μm/pore size), as described previously.19 Briefly, the lower side of the filter was coated with 10 μg/mL fibronectin. Approximately 1×104 cells were added in the upper chamber and allowed to migrate through the filter toward the lower chamber containing serum free medium (0.2% bovine serum albumin) with or without SEMA3A, in the presence of 15 μg/mL purified anti-NP1 blocking antibody20 or an unrelated antibody (anti-VSVG). Cell migration was allowed for 16 to 18 hours; the cells adherent to the upper side of the filter were mechanically removed, whereas those migrated to the lower side were fixed with 11% glutaraldehyde and stained with crystal violet. The dye was solubilized in 10% acetic acid to measure absorbance at 595 nm in a microplate reader.

Mouse Tumor Models

Six- to 8-week-old CD1 athymic mice and Balb/c mice were purchased from Charles River Laboratory (Calco, Milan, Italy). FVB/Tie2-GFP transgenic mice were generated by LV-mediated transgenesis, as described.17 For tumorigenesis experiments, depending on the cancer cell line used, 2×106 MDA-MB-435, 1×106 66cl4, or 1×106 4T1 cells were injected subcutaneously into the flank or the mammary fat pad of anesthetized animals. Tumor size was measured externally using a caliper, and tumor volume was estimated using the following equation: V=4/3π×(d/2)^2×D/2, where d is the minor tumor axis and D is the major tumor axis. Mice were typically euthanized 3 weeks after tumor cell injection (unless otherwise indicated in the manuscript), and tumors weighted after dissection. Superficial pulmonary metastases were contrasted by black India-ink airways infusion, and counted on dissected lung lobes under a stereoscopic microscope. For orthotopic tumor cell injection, 1×106 4T1 or 1×106 4T1 66cl4 cells were resuspended in 40 μL of phosphate-buffered saline and injected into the second mammary fat pad of anesthetized Balb/c mice. Mice were euthanized after 15 or 19 days, respectively, and tumor and lungs were analyzed as described above. For systemic delivery of SEMA3A in vivo, concentrated PGK-3A and control LVs were administered by tail vein injection in 6- to 8-week-old Balb/c mice, 2 weeks before subcutaneous tumor cell injection.

All animal procedures were performed according to protocols approved by the animal experimentation supervising boards of the University of Torino, Fondazione San Raffaele del Monte Tabor (Milan, Italy), and Uppsala University.

Experimental Metastasis Assays

4T1 cancer cells (2.5×105 cells) were injected in the lateral tail vein of CD1 athymic mice; the formation of metastatic colonies in the lungs was analyzed 8 days later by black India ink airways infusion, as described above. For short-term experiments evaluating the metastatic extravasation of fluorescent 4T1 cells, we labeled cancer cells in culture by a short incubation with 10 μmol/L CFDA SE Vybrant cell tracker (Molecular probes) according to the manufacturer’s instructions, before cell injection in the tail vein.21 Tumor cell colonization of lung tissue was analyzed 48 hours later in at least 5 pairs of lungs in each experimental group (10 independent microscopic fields/lung) using the Metamorph software.

Metastatic Cell Clonogenic Assays

These assays were performed as described previously.18 After euthanasia, the lungs, lymph nodes, brain and liver were removed from tumor-bearing mice, minced into pieces, and incubated with a cocktail containing 1.5 mg/mL collagenase type IV (Sigma) and 2 mg/mL dispase (Sigma) at 37°C. Tissue samples were then mechanically dispersed and passed through 19- and 25-gauge needles to form a single cell suspension, which was plated out in complete culture medium supplemented with 60 μmol/L 6-thioguanine. After 10 to 12 days, growing colonies were fixed with methanol, stained with crystal violet, and counted under a dissection microscope.

Hematopoietic Stem/Progenitor Cell Transduction and Transplantation

Six-week-old female CD1 athymic, FVB, and FVB/Tie2-GFP and mice were killed with CO2, and their bone marrow (BM) was harvested by flushing the femurs and the tibias. Lineage-negative cells enriched in hematopoietic stem/progenitor cells were isolated from BM cells using a cell purification kit (Stem Cell Technologies) and transduced by concentrated LVs, as described.22,23 Briefly, 106 cells/mL were transduced with a LV dose equivalent to 3 to 4 μg/mL
HIV p24 (for Tie2-Sema3A and PGK-Sema3A LVs) or 10^6 GFP transducing units/mL (for Tie2-GFP and PGK-GFP LVs) for 12 hours in serum-free StemSpan medium (Stem Cell Technologies) containing a cocktail of cytokines (interleukin-3 [10 ng/mL], interleukin-6 [20 ng/mL], SCF [100 ng/mL], and Fms-related tyrosine kinase 3 ligand [10 ng/mL], all from Serotec). After transduction, 10^6 cells were infused into the tail vein of lethally irradiated, 6-week-old female CD1 athymic mice (radiation doses: 975 cGy).

Vector copy number in BM cells was measured by quantitative polymerase chain reaction of vector sequences at the end of the experiments, as described. Colony forming cell assays were performed as described. The engraftment of hematopoietic stem/progenitor cells transduced with the Tie2-SEMA3A-myc LV was assessed in transplanted mice by anti-Tie2 and anti-myc immunostaining of circulating cells, using a BD FACSCanto (BD Bioscience) analyzer.

Hypoxia and Tumor Perfusion

Tumor hypoxia was detected 2 hours after injection of 60 mg/kg pimonidazole hydrochloride in tumor-bearing mice. Mice were then euthanized, and tumors were harvested. To detect the formation of pimonidazole adducts, tumor paraffin sections were immunostained with Hypoxprobe-1-Mab1 (Hypoxprobe kit, Chemicon) following the manufacturer’s instructions. Blood vessel permeability was detected by intravenous injection of 0.05 mg of 70-kDa fluorescein isothiocyanate (FITC)–conjugated dextran or biotin-conjugated dextran (Molecular Probes) and of 0.05 mg of FITC-conjugated Tomato Lectin (Vector Laboratories) in tumor-bearing mice; this relatively small molecule extravasates readily from leaky tumor blood vessels. Ten minutes later, mice were perfused by intracardiac injection of saline and 2% paraformaldehyde (5 minutes) and the tumors harvested and frozen in OCT compound. Blood vessel permeability was analyzed by measuring the area of extravasated dextran. Blood vessel perfusion was analyzed by injecting 0.05 mg of nonpermeable high-molecular-weight tetrathymethylrhodamine-labeled dextran (2 MDA, Molecular Probes) in tumor-bearing mice, 10 minutes before tumor excision. Tumors were then fixed in 4% paraformaldehyde for 2 hours and frozen in OCT compound for immunofluorescence analysis.

Histological Analysis

Tumors samples were frozen in OCT compound, cut in 10-μm thick sections, and immunostained with the appropriate antibodies, directed to cleaved caspase-3 (5A1E, Cell Signaling), myc (9E10, Santa Cruz Biotechnology), CD31, CD11b (BD Biosciences), F4/80 (Serotec), NG2 (Millipore), LYVE-1 (R&D Systems), Tie2 (eBioSciences), α-smooth muscle actin (α-SMA)–FITC (Sigma), and cleaved caspase-3 (Cell Signaling). Streptavidin and all secondary antibodies were conjugated with Alexa Fluor 488 or Alexa Fluor 546 fluorochromes (Molecular Probes). Cell nuclei were labeled with 4’,6-diamidino-2-phenylindole (Invitrogen Corp). Multiple independent fields from sections of at least 4 tumors for each experimental condition were analyzed by using a Leica DM IRBM microscope, a Nikon TE300 Eclipse inverted fluorescence microscope, or a LSM 510 META confocal microscope and quantified by ImageJ software.

Statistical Analyses

Throughout the study, graphs always show average values ± standard deviation (SD) unless otherwise indicated. Statistical analyses were performed by unpaired Student t test or 2-way ANOVA, as indicated. Stars in the graphs indicate significance, as detailed in the figure legends. Differences were considered statistically significant at P < 0.05.

Results

SEMA3A Inhibits Tumor Growth and Metastatic Progression

To investigate the role of SEMA3A in tumor cell behavior and progression, we transduced 3 different tumor cell lines (4T1 and 66cl4 mammary carcinoma and MDA-MB-435 melanoma cells) with a SEMA3A-expressing LV, and obtained 3A+ cells. Control cells were generated by transducing the aforementioned tumor cell lines with a LV lacking the SEMA3A cDNA (referred to as empty vector [EV] cells). We confirmed SEMA3A expression in transduced cells by Western blotting (Figure 1A and Supplemental Figure IA, available online at http://atvb.ahajournals.org). Notably, in addition to endothelial cells, the SEMA3A receptor NP1 is expressed in most tumor cells, including those used in our study (see Supplemental Figure II). Although it has been reported that SEMA3A can inhibit the growth of certain tumor cell lines in an NP1-dependent manner, in our experiments, SEMA3A overexpression did not affect tumor cell proliferation, even on serum deprivation (Figure 1B and 1C and Supplemental Figure IB). However, SEMA3A strongly inhibited tumor cell migration via NP1, as demonstrated by using an NP1-blocking antibody (Figure 1D and 1E and Supplemental Figure IC).

Despite the fact that SEMA3A autocrine loop in tumor cells did not affect cell proliferation or survival in vitro, when these engineered cells were implanted in vivo, we found that tumor growth was strongly inhibited by SEMA3A expression (Figure 1F and 1G and Supplemental Figure ID and IH). Moreover, 3A+ tumor-bearing mice displayed fewer spontaneous lung metastatic nodules compared with controls (Figure 1H and Supplemental Figure IE). Because SEMA3A proved to actively inhibit tumor cell migration in vitro, we aimed at better understanding the role of SEMA3A in controlling metastatic dissemination. We then introduced fluorescently labeled 4T1-EV and 4T1–3A+ tumor cells in the tail vein, and 48 hours postinjection, we scored the number of tumor cells colonizing the lungs. Notably, SEMA3A expression strongly reduced the number of tumor cells that successfully extravasated and colonized the lungs (Figure 1I), indicating that this semaphorin can directly regulate metastasis formation.

4T1 tumor cells are known to spread to additional metastatic sites beyond the lungs, such as lymph nodes, liver and brain, whereas 66cl4 mainly spread via the lymphatic route to the lungs. To investigate whether SEMA3A also affects metastatic dissemination to other distant organs, we injected 4T1 and 66cl4 control-EV or 3A+ cells in the mammary fat pad of wild-type female mice to produce orthotopic mammary tumors. After 15 days, we euthanized the mice and harvested the liver, brain, lungs, draining lymph nodes and blood. Dissociated cells from the different organs were then subjected to clonogenic assays in culture, in the presence of the selection drug 6-thioguanine, for which both 4T1 and 66cl4 cells carry the resistance gene. In line with previous reports, 66cl4-EV tumor cells formed several colonies from lymph nodes and few colonies from the lung (Figure 1J), but none from liver, brain, or blood. On the other hand, 4T1-EV tumor cells readily formed tumor cell colonies from the lung, and, to a lesser extent, from liver, lymph nodes, and brain (Figure 1K). SEMA3A expression in 66cl4 and 4T1 tumor cells significantly decreased the number of colony-forming metastatic cells in each of the
Effects on Tumor Vasculature

The findings above strongly suggested that SEMA3A-dependent inhibition of tumor growth seen in our experiments was due to a paracrine effect in the tumor microenvironment. To study the implicated mechanisms, we therefore analyzed tissue sections derived from primary tumors. We found that 4T1- and 66cl4–3A+ tumors displayed 25% increased necrotic areas compared with controls (Supplemental Figure III). Moreover, SEMA3A+ tumors displayed higher proportions of the apoptotic marker cleaved caspase-3 in tumor and endothelial cells compared with controls (Figure 3A, Supplemental Figure III). SEMA3A+ tumors displayed higher proportions of the apoptotic marker cleaved caspase-3 in tumor and endothelial cells compared with controls (Figure 3A, Supplemental Figure III). SEMA3A+ tumors displayed higher proportions of the apoptotic marker cleaved caspase-3 in tumor and endothelial cells compared with controls (Figure 3A, Supplemental Figure III).
Double staining for CD31 and the pericyte markers α-SMA and NG2 indicated that SEMA3A expression by tumor cells impaired pericyte coverage of tumor blood vessels (Figure 3C).

Because Sema3A reduced 66cl4 tumor cell spreading to lungs and lymphatics, we investigated whether SEMA3A-expressing tumors displayed any defects in lymphangiogenesis. To this end, we stained tumor sections with antibodies against LYVE-1, which labels lymphatic vessels and a subset of F4/80+ tumor-associated macrophages. Interestingly, 3A+ tumors displayed fewer lymphatic vessels, as shown by the reduced relative area of LYVE-1+ F4/80− CD31− vascular structures (Supplemental Figure V).

Systemic Delivery of SEMA3A Efficiently Inhibits Tumor Progression

Once a tumor has disseminated to distant organs, the local delivery of tumor suppressor molecules may not be a therapeutically feasible strategy. Thus, we assessed the potential antitumor activity of SEMA3A in a model of systemic delivery in vivo. We used a previously validated strategy to achieve systemic expression of secreted factors in tumor-recipient mice. On injection in the venous circulation, LVs preferentially transduce the liver and the spleen, where they establish a stable source of the transgene product. By this approach, we generated mice stably expressing SEMA3A (here referred to as s-SEMA3A mice), or control mice (s-EV mice). SEMA3A expression was detected in the liver by immunohistochemistry (Supplemental Figure VI) and in blood samples by ELISA (estimated levels: 95% confidence interval = 77.06 to 94.58 ng/mL). SEMA3A-treated mice did not display histological abnormalities or increased apoptosis in the liver (data not shown), nor did they show any significant change in blood lymphocyte or erythrocyte counts and hemoglobin levels (data not shown).

4T1 or 66cl4 metastatic mammary carcinoma cells were then transplanted subcutaneously in syngeneic s-Sema3A and control mice. Analogously to what was observed on SEMA3A overexpression in cancer cells, the systemic expression of SEMA3A efficiently inhibited 4T1 and 66cl4 tumor growth (Figure 4A) and metastatic dissemination in mice (Figure 4B). Notably (and consistent with data shown in Figure 1D and 1E), 4T1 and 66cl4 tumor cell migration in vitro was strongly inhibited by exogenous SEMA3A (Figure 4C). To further elucidate the antimitastatic effect of SEMA3A, systemic delivery of SEMA3A was compared with its overexpression in 4T1−3A+ cells, in a model of experimental lung metastasis that is independent of the growth of primary tumors. Both systemic and tumor cell-based expression of SEMA3A impaired the formation of lung metastatic colonies by 4T1 cells systemically injected in the mouse circulation (Figure 4D), further supporting the hypothesis that SEMA3A has a direct effect on tumor cell extravasation and lung colonization.

We then investigated whether the systemic delivery of SEMA3A produced the same effects on tumor vasculature and apoptosis in primary tumors as its overexpression in tumor cells. CD31 staining of tumor sections revealed that the relative vessel area was reduced in 4T1 and 66cl4 tumors.
Figure 4. Systemic delivery of SEMA3A inhibits breast cancer progression and angiogenesis. A and B, Systemic delivery of SEMA3A reduced tumor burden (A) and spontaneous metastatic dissemination to the lungs (B) of 66cl4 and 4T1 cancer cells implanted subcutaneously into syngeneic mice (left and right graphs, respectively) (n = 6; ***P < 0.001). C, Cancer cell migration was analyzed by Transwell migration assay, in the presence of either SEMA3A or control EV (as described above) (n = 6; ***P < 0.001). Scale bars, 50 μm. D and E, Tissue sections grown in s-SEMA3A or control EV mice were immunostained for CD31 (red), and FITC-conjugated dextran appears in green. Morphometric analysis revealed increase of extravasated dextran in SEMA3A-treated tumors compared with controls (n = 6; ***P < 0.001). Scale bars, 50 μm. F, Tissue sections of 66cl4 and 4T1 tumors grown in presence of systemic SEMA3A or EV were immunostained for the endothelial cell marker CD31 (red) to visualize blood vessels (E) and for cleaved caspase 3 (green) to visualize apoptotic cells (F). The systemic delivery of SEMA3A reduced vessel area and induced tumor cell and tumor vessel apoptosis (n = 6; ***P < 0.001, **P < 0.01). White arrows point to apoptotic vessels. The images depict representative 4T1-EV and SEMA3A” tumor sections (upper panel of F). Scale bars, 20 μm (E) and 50 μm (F).

Figure 5. Systemic delivery of SEMA3A alters vessel functionality. A, Sections from 4T1 tumors with or without systemic delivery of SEMA3A were coimmunostained for the endothelial marker CD31 and the pericyte markers NG2 (upper row) or α-SMA (lower row) to assess vessel structure. Morphometric analysis showed a decrease in pericyte-covered tumor vessels in SEMA3A-treated tumors compared with controls (n = 6; *P < 0.05, **P < 0.01). Scale bars, 20 μm. B, Tumor-bearing mice (as described above) were injected with 70-kDa FITC-conjugated dextran to visualize vessel permeability. 4T1 tumor sections grown in s-SEMA3A or control EV mice were immunostained for CD31 (red), and FITC-conjugated dextran appears in green. Morphometric analysis revealed increase of extravasated dextran in SEMA3A-treated tumors compared with controls (n = 6; **P < 0.01). Scale bars, 50 μm. C, 4T1 tumor-bearing mice exposed to systemic SEMA3A or EV were injected with pimonidazole (PIMO) to detect hypoxic areas. Immunohistochemistry staining for PIMO (revealed by horseradish peroxidase substrate in brown) showed that systemic SEMA3A increased tumor hypoxic areas compared with controls (n = 6; ***P < 0.001). Scale bars, 50 μm.
though promoting a prometastatic tumor microenvironment (enhanced hypoxia and vascular leakiness), efficiently inhibits metastatic dissemination of tumor cells by exerting direct effects on tumor cells.

**Tumor-Targeted Delivery of SEMA3A by TIE2-Expressing Monocytes Inhibits Tumor Progression**

A subset of circulating and tumor-infiltrating proangiogenic monocytes/macrophages, which are characterized by the expression of the angiopoietin receptor Tie2 (Tie2-expressing monocytes [TEMs]), were recently exploited to deliver interferon-α to the tumor site. These cells are derived from the bone marrow and can be used as cellular vehicles to achieve targeted delivery of inhibitory molecules to tumors, without generating high systemic blood concentrations of the secreted factor. To accomplish TEM-mediated delivery of SEMA3A to tumors, we produced LVs expressing the murine SEMA3A cDNA under the control of promoter/enhancer sequences of the Tie2 gene (Tie2-3A LV). Consistent with the notion that Tie2 is highly expressed in endothelial cells, the Tie2-3A LV expressed SEMA3A efficiently in brain endothelial cells but not in embryonic kidney HEK-293T cells in vitro (see Supplemental Figure VIIA).

Hematopoietic stem/progenitor cells obtained from the BM of FVB-Tie2-GFP transgenic mice or FVB-WT mice were then transduced with the Tie2-3A LV and transplanted into lethally irradiated mice, to obtain mice with TEM-specific expression of m-SEMA3A (Tie2-SEMA3A mice; see schematic procedure in Supplemental Figure VIII). Moreover, mice transplanted with BM cells transduced with Tie2-EV LVs were used as controls. Tie2-SEMA3A mice were reconstituted long-term by SEMA3A gene-modified BM cells and did not show any obvious signs of toxicity (data not shown).

Six weeks after hematopoietic stem/progenitor cell transplantation, 66cl4 mammary carcinoma cells were injected subcutaneously in both Tie2-3A and control mice to study tumor development. At the end of the experiments (6 weeks after tumor cell injection), we found that both primary tumor weight (Figure 6A) and metastatic spreading (Figure 6B) were reduced in Tie2-3A mice as compared with the controls. Notably, Tie2-Sema3A expression did not affect the number of circulating TEMs as estimated by fluorescence-activated cell sorting analysis of Tie2<sup>+</sup>CD115<sup>+</sup> cells in the peripheral blood of Tie2-3A and Tie2-EV mice (1.02±0.39% versus 1.26±0.45% of total leukocytes, respectively; P=0.69; n=6). Moreover we found blood vessel–associated Tie2<sup>+</sup> cells<sup>17,29</sup> positive for SEMA3A expression (Figure 6C).

Immunostaining of tumor sections revealed that TEM-mediated SEMA3A delivery phenocopied the vascular changes observed on systemic delivery of SEMA3A. In particular, CD31 immunostaining indicated that tumors grown in Tie2-Sema3A mice had reduced relative blood vessel area (Figure 6D). Moreover, SEMA3A greatly impaired vessel functionality, as revealed by labeling perfused blood vessels with high-molecular-weight (2 Mda) TRITC-conjugated dextran injected in the circulation of tumor-bearing mice (Figure 6E). Consistent with the data observed in mice that received systemic SEMA3A, pericyte coverage is substantially reduced in Tie2-SEMA3A tumors (A and B, 66cl4 tumors were coimmunostained for CD31 and fluorescent dextran in red). TEM cell–mediated delivery of SEMA3A reduced the number of perfused vessels (identified by double staining for CD31 (red), cleaved-caspase 3 (green), and TOPRO3 (blue). Scale bars, 20 μm. D, Sections from the same tumors as described above were immunostained for CD31 (red) revealed that TEM cell–mediated delivery decreased vessel area compared with controls (n=12, **P<0.01; the graphs display average values±SEMs). Scale bars, 20 μm. E, Functional and blood-perfused vessels were labeled by injecting nonpermeable high-molecular weight (2-MDa) tetramethylrhodamine-dextran (red) in tumor-bearing mice (same as described above), as well as staining for CD31 (in blue). TEM cell–mediated delivery of SEMA3A reduced the number of perfused vessels (identified by double staining for CD31 in blue and fluorescent dextran in red (n=6 **P<0.05). Scale bars, 20 μm. F, Tumor sections from control and Tie2-3A 66cl4 tumors were immunostained for CD31 (red) and the pericyte marker α-SMA (green). Morphometric analysis (second row) showed less pericyte-covered tumor vessels in Tie2-3A tumors compared with controls (n=12, **P<0.01; the graphs display average values±SEMs). Scale bar, 20 μm. G, Sections as described above were immunostained for CD31 (red), cleaved-caspase 3 (green), and Topro3 (blue). SEMA3A treated tumors displayed an increase in apoptotic vessels (n=12, **P<0.01; the graphs display average values±SEMs). White arrows point to apoptotic vessels. Scale bars, 20 μm. H, Tumors were also immunostained for the hypoxic marker pimonidazole (PIMOC; red) and for the nucleic marker Topro3 (blue). Morphometric analysis showed an increase in hypoxia in Tie2-3A tumors compared with controls (n=6; **P<0.05). Scale bars, 100 μm.

![Figure 6. TEM cell-mediated SEMA3A delivery to the tumor site inhibits tumor progression. A and B, 66cl4 tumor growth in nude mice transplanted with Tie2-3A (transduced bone marrow). TEM cell-mediated delivery of SEMA3A reduced tumor growth (A) and metastatic dissemination (B) (n=20; **P<0.01, *P<0.05; the graphs display average values±SEMs). C, Sections from Tie2-EV and Tie2-3A 66cl4 tumors were immunostained to detect Tie2 (red) and myc-tagged SEMA3A (green). Scale bars, 20 μm. D, Sections from the same tumors as described above were immunostained for CD31 (red) revealed that TEM cell-mediated delivery decreased vessel area compared with controls (n=12, **P<0.01; the graphs display average values±SEMs). Scale bars, 20 μm. E, Functional and blood-perfused vessels were labeled by injecting nonpermeable high-molecular weight (2 Mda) tetramethylrhodamine-dextran (red) in tumor-bearing mice (same as described above), as well as staining for CD31 (in blue). TEM cell-mediated delivery of SEMA3A reduced the number of perfused vessels (identified by double staining for CD31 in blue and fluorescent dextran in red (n=6 **P<0.05). Scale bars, 20 μm. F, Tumor sections from control and Tie2-3A 66cl4 tumors were immunostained for CD31 (red) and the pericyte marker α-SMA (green). Morphometric analysis (second row) showed less pericyte-covered tumor vessels in Tie2-3A tumors compared with controls (n=12, **P<0.01; the graphs display average values±SEMs). Scale bar, 20 μm. G, Sections as described above were immunostained for CD31 (red), cleaved-caspase 3 (green), and Topro3 (blue). SEMA3A treated tumors displayed an increase in apoptotic vessels (n=12, **P<0.01; the graphs display average values±SEMs). White arrows point to apoptotic vessels. Scale bars, 20 μm. H, Tumors were also immunostained for the hypoxic marker pimonidazole (PIMOC; red) and for the nucleic marker Topro3 (blue). Morphometric analysis showed an increase in hypoxia in Tie2-3A tumors compared with controls (n=6; **P<0.05). Scale bars, 100 μm.](http://atvb.ahajournals.org/)
of tumor vessels in Tie2-Sema3A mice was reduced (Figure 6F). Moreover, double staining for cleaved caspase-3 and CD31 showed that Tie2-Sema3A tumors contained a significantly increased fraction of apoptotic endothelial cells compared with controls (Figure 6G). The reduced blood vessel functionality in tumors grown in Tie2-Sema3A mice translated in an increased tumor hypoxia, as assessed by pimonidazole staining (Figure 6H). These data indicate that TEM-mediated delivery of Sema3A can impair blood vessel formation and functionality, as well as the growth of primary tumors and their metastatic dissemination to the lungs.

Discussion

Solid tumors cannot grow or spread without the formation of new blood vessels; this finding has driven several studies in the last decades aimed to find antiangiogenic therapeutic strategies. In this work, we have investigated the role of Sema3A in tumor angiogenesis, tumor growth and metastatic dissemination using 3 different delivery strategies: (1) tumor cell-based gene transfer, (2) systemic expression of Sema3A in mice, and (3) tumor macrophage-mediated local delivery in tumors. Although it has been reported that an autocrine loop of Sema3A may inhibit the growth of tumor cells expressing high levels of NP1, we did not observe this effect in various tumor cell models analyzed in this study. However, Sema3A did inhibit tumor cell migration in an NP1-dependent manner.

Recent studies have emphasized that tumor growth and metastatic dissemination is regulated not only by blood vessel density but, most importantly, by blood vessel functionality. The tumor vasculature typically displays a high-density irregular network, and it is often characterized by inadequate coverage by mural cells; this inadequate coverage has also been implicated in the metastatic spreading. An abnormal tumor vasculature is generally poorly perfused, which results in enhanced tumor cell apoptosis, necrosis and hypoxia. Therapeutic approaches aimed at further reducing vessel perfusion usually impair tumor growth; this may also affect metastasis formation as a secondary effect to the reduction of primary tumor burden. However, it has recently been shown that tumor shrinkage achieved by antiangiogenic drugs interfering with vascular endothelial growth factor signaling may instead be associated with increased metastatic spreading. Although the molecular mechanisms responsible for these processes are currently unknown, it has been proposed that hypoxic tissues switch on a transcriptional “escape” program, leading to increased cancer cell invasiveness.

In our study, we demonstrated that systemic or local expression of Sema3A impairs tumor angiogenesis and reduces the number of pericyte-coated vessels. This resulted in decreased vessel perfusion and increased hypoxia, in association with tissue apoptosis and necrosis; thus, Sema3A-treated tumors were significantly smaller than controls. Importantly, although hypoxic and apoptotic, these tumors did not become invasive and metastatic, suggesting that Sema3A could concomitantly interfere with cancer cell behavior. In fact, we showed that, independently from its paracrine activity on tumor vasculature, Sema3A inhibits the metastatic dissemination by acting directly on cancer cell migration in NP1-dependent manner. This was demonstrated by distinct experimental strategies: (1) NP1-neutralizing antibodies abrogated Sema3A-dependent inhibition of tumor cell migration, and (2) NP1 expression knockdown in cancer cells prevented Sema3A-mediated inhibition of metastatic dissemination in vivo.

Importantly, the potency of the antiangiogenic activity of Sema3A will depend on the active concentration that is reached within the tumor site and tumor vessels and on its ability to counterbalance the effect of proangiogenic factors usually present in the tumor microenvironment. For instance, the local delivery of Sema3A in a transgenic oncogene-driven model of pancreatic islet cell carcinogenesis resulted in a mild and transient antiangiogenic effect, which eventually subsided into vessel “normalization” rather than further disruption. This resulted in a moderate Sema3A-dependent inhibition of tumor growth that was sufficient to prolong overall survival by delaying the occurrence of lethal hyperinsulinemia; however, time persistence of tumor suppression and potential metastatic progression were not investigated. In our present study, by exploiting multiple experimental tumor models and delivery routes based on LV-mediated gene transfer, we demonstrated that Sema3A is a strong antiangiogenic factor novel in its kind, because it can impair tumor growth and prevent metastatic dissemination. In our experiments, the majority of vessels in Sema3A-treated tumors were severely disrupted compared with controls, indicating a persistent inhibitory activity by the semaphorin, which overpowered local proangiogenic factors and resulted in sustained tumor suppression during the entire experiment. Moreover, we showed that the metastatic spreading was not increased in presence of Sema3A, because this versatile antiangiogenic factor also directly inhibited cancer cell migration.

In conclusion, our work provides proof of concept, in multiple preclinical models, that the antiangiogenic activity of Sema3A may be exploited to effectively inhibit tumor growth and metastatic progression.

Acknowledgments

We thank L. Palmas, S. Giove, and L. Fontani for skilful technical assistance. Anti-NP1 antibodies were generously provided by A. Kolodkin (Johns Hopkins University, Baltimore, MD).

Sources of Funding

This work was supported by a grant from Italian Association for Cancer Research and from Regione Piemonte (to L.T.), a grant from the Italian Association for Cancer Research (to L.N.), a European Research Council (ERC) Starting Grant (to M.D.P.), Swedish Cancer Foundation Project CAN 2008/980, Marie Curie Re-Integration Grant Contract MERG-CT-2007-046454, and an Åke Wibergs Grant (to C.R.). A.C. was supported by an Italian Foundation for Cancer Research and from Regione Piemonte (to L.T.), a grant from Italian Association for Cancer Research (FIRC) fellowship.

Disclosures

None.

References


18. Casazza et al SEMA3A Inhibits Tumor Progression and Angiogenesis 749
SUPPLEMENTAL MATERIAL

Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models

by Andrea Casazza et al.

SUPPLEMENTAL METHODS

Real-time Quantitative PCR analysis of NP1 gene expression. Total RNA from tumor cell lines was isolated by using RNeasy Protect Mini Kit (Qiagen) according to manufacturer’s instructions. cDNA preparation was performed according to standard procedures, using M-MLV Reverse Transcriptase (Promega) and oligo-dT primers (Sigma-Genosys). Q-PCR analysis was performed using the Applied Biosystems 7900HT Fast Real-time PCR System and Taqman probes Hs00826128_m1 (human NP1) and Mm00435372_m1 (mouse NP1). Gene expression was quantified as relative number of transcripts compared to HPRT (Taqman probes: Hs99999909_m1, Mm01545399_m1, human and murine, respectively).

ELISA-based SEMA3A quantification of SEMA3A in mouse sera. Anti-SEMA3A antibody (Abcam) was adsorbed to 96-well ELISA plates overnight at 4°C. After blocking non-specific binding, multiple dilutions of serum samples and a standard curve of purified SEMA3A (0–100 ng/mL) were incubated overnight at 4°C. Captured SEMA3A was revealed with anti-myc-tag antibodies conjugated with horseradish peroxidase (Roche). Enzymatic reaction was developed in the presence of tetramethylbenzidine (Sigma) as substrate, and the colorimetric analysis was performed with ELx-800 reader (BioTek Instrument, Inc.). SEMA3A concentration in serum samples was determined by interpolation of absorbance values with those of the standard curve.
**HUVEC-Tumor Cell Co-Culture Assay.** HUVEC cells repulsion by co-cultured tumor cells was measured as described previously (Bielenberg et al., 2004), with the following modifications. HUVEC cells were grown to confluence into 24-well cell culture dishes (Corning Inc.) onto gelatin-coated glass cover slips. The endothelial cell monolayer was washed twice and $4 \times 10^3$ MDA-MB435 tumor cells were seeded out on the monolayer, transduced with SEMA3A, were seeded onto it in D-MEM complete medium. Co-cultures were incubated for 24h and 48 h, before analysis. Cells were then fixed with PAF and subjected to immunostaining. Endothelial cells were identified by immunocytochemical staining with anti-CD31 antibodies (DAKO). Apoptotic cells were identified with anti-cleaved Caspase-3 (Cell Signaling).

**Cited References**


**SUPPLEMENTAL FIGURE LEGENDS**

**Supplemental Figure I.**

**Tumor growth is inhibited by cell-based therapy with SEMA3A.**

**A:** Western blotting analysis revealed the expression of myc-tagged h-SEMA3A in protein lysates of LV-transduced human MDA-MB-435 (MDA). Control cells were transduced with an empty vector (EV).

**B:** Cell growth curves show that MDA-EV and MDA-3A$^+$ tumor cells grew at comparable rates in low serum conditions (1% FBS),
C: MDA-EV and 3A⁺ cell migration was analyzed in a Transwell migration assay. MDA-EV and 3A⁺ cells were allowed to migrate towards 1% FBS-containing medium, supplemented with a control antibody or a NP1-blocking antibody. The migration of 3A⁺ cells was reduced compared to control cells, but NP1-neutralizing antibodies prevented the inhibitory effect of SEMA3A. Asterisks (*) indicate statistically significant differences compared to MDA EV cells treated with control Ab ***p<0.001 while hatch (##) indicate significance compared to MDA-3A⁺ treated with control Ab ## p<0.01.

D-E: SEMA3A-expressing and EV-control transduced tumor cells described above were transplanted subcutaneously into athymic mice. SEMA3A expression significantly reduced tumor growth (D) and metastatic dissemination to the lungs (E) (n=6; ***p<0.001, **p<0.01, *p<0.05; with 2-Way ANOVA and Students t-test).

F-G: MDA-EV and 3A⁺ tumor sections were to immunostaining for activated-caspase3 to detect apoptotic cells (in green); CD31 marker was stained to identify endothelial cells (red); DAPI stained all nuclei (blue). SEMA3A increased tumor cell apoptosis (i.e. caspase⁺ cells/total cell number; panel F) and decreased vessel area (panel G) (n=6; *p<0.05, **p<0.01). Scale bars: 20 µm (panel F) and 50 µm (panel G).

H: Immunostaining of MDA-EV and 3A⁺ tumor sections revealed the expression of secreted myc-tagged SEMA3A (green); nuclei were stained with DAPI (blue). Scale bars: 20 µm.

Supplemental Figure II.
Neuropilin-1 expression in tumor models.

A: Neuropilin-1 (NP1) expression in three cancer cell lines used in our study was determined by Q-PCR. The graph displays the relative number of NP1 mRNA transcripts compared to those of HPRT house-keeper gene in each of the models.
B: Neuropilin-1 (NP1) and Plexin-A1 expression in 4T1, 66cl4 and MDA control EV-cells and SEMA3A-transduced cells was determined by Q-PCR.

C: 66cl4 and 4T1 tumor tissue sections were stained to reveal NP1 (green) and CD31-positive endothelial cells (red)(n=5).

Supplemental Figure III.
SEMA3A increase necrosis and hemorrhagis in 4T1 and 66cl4 Tumors.
Tissue sections of control-EV and SEMA3A+ tumors (66cl4 and 4T1, as indicated) were stained with hematoxylin and eosin to detect necrotic (N) and hemorrhagic (H) areas (n= 6; *p <0.05; **p <0.01). Scale bars: 100 μm.

Supplemental Figure IV.
SEMA3A induce endothelial cell apoptosis in vitro.
MDA-3A+ and MDA-EV were co-cultured with HUVEC cells during 24 and 48 hours. SEMA3A induced endothelial apoptosis as measured by staining for the endothelial marker CD31 and the apoptosis marker cleaved caspase-3 (bottom panel, number of field counted=10; ***p<0.001). Green arrows indicate apoptotic cells while white arrow indicates tumor cells.

Supplemental Figure V.
SEMA3A inhibits lymphangiogenesis.
Tissue sections of 4T1-EV and 3A+ tumors were co-stained to reveal the network of lymphatic vessels, by using the marker LYVE-1, in association with CD31 and F4/80. SEMA3A expression reduced LYVE-1+F4/80CD31– lymphatic vessels by 50% compared to controls in both tumor models (n=6; **p<0.01, *p<0.05). Scale bars: 20 μm.
**Supplemental Figure VI.**

**Systemic delivery of SEMA3A in mice.**
Liver sections from control and s-Sema3A mice were stained with anti-myc to detect myc-tagged Sema3A expression. Scale bars: 100 μm.

**Supplemental Figure VII.**

**Generation of Mice with TEM-Specific Expression of SEMA3A.**

A: Tie2-2 driven expression of SEMA3A is detected by western blotting analysis in brain endothelial cells (bEND) but not in HEK-293T cells.

B: Schematic figure describing the experimental procedure applied to generate chimeric mice with TEM-Specific Expression of SEMA3A.
Supplemental Figure I

A. MDA Tumor Cell Proliferation

B. MDA Tumor Cell Migration

C. MDA Tumor Volume

D. MDA Lung Metastasis

E. MDA Tumor Cell Apoptosis

F. MDA Angiogenesis

G. Caspase3 DAPI CD31

H. CD31

G. Myc DAPI
Supplemental Figure II

A.

NP1 copies/1000 HPRT copies

- 66cl4
- 4T1
- MDA

B.

Neuropilin-1 expression (fold change)

- 4T1
- 66cl4
- MDA

Plexin-A1 expression (fold change)

- 4T1
- 66cl4
- MDA

C.

4T1

CD31

66cl4

NP1

CD31 NP1
Supplemental Figure IV

A.  

B.  

Downloaded from http://atvb.ahajournals.org/ by guest on June 12, 2012
Supplemental Figure V

LYVE-1+ CD31- F4/80- (%)

66cl4 EV 3A

4T1

LYVE-1 CD31 F4/80
Supplemental Figure VI

anti-MYC